Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors

被引：1
|
作者：
Issa, M. [1 ]
Klamer, B. [2 ]
Bhateja, P. [3 ]
Karivedu, V. [3 ]
Laliotis, G. [4 ]
Dibs, K. [5 ]
Mladkova, N. [5 ]
Pan, X.
Old, M. [5 ]
Gamez, M. [5 ]
Grecula, J. [5 ]
Jhawar, S. [5 ]
Mitchell, D. [5 ]
Baliga, S. [5 ]
Carrau, R. [6 ]
Rocco, J. [6 ]
Bonomi, M. [3 ]
Blakaj, D.
机构：
[1] Ohio State Univ, Med Oncol, James Canc Hosp, Columbus, OH USA
[2] Ohio State Univ, Sch Biomed Sci, Ctr Biostat, OSUCCC,Comprehens Canc Ctr, Columbus, OH USA
[3] Ohio State Univ, Dept Med Oncol, OSUCCC, Comprehens Canc Ctr, Columbus, OH USA
[4] Sidney Kimmel Comprehensive Canc Ctr, Med Oncol, Baltimore, MD USA
[5] Ohio State Univ, Radiat Oncol, Comprehens Canc Ctr, OSUCCC, Columbus, OH USA
[6] Ohio State Univ, Otolaryngol, James Canc Hosp, Columbus, OH USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
888P
引用
收藏
页码：S797 / S798
页数：2
相关论文
共 50 条
  • [31] Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy
    Chen, Wen-qing
    Peng, Liang
    Zeng, Xue-lan
    Wen, Wei-ping
    Sun, Wei
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
  • [32] Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck
    Tanaka, Hideki
    Enokida, Tomohiro
    Okano, Susumu
    Fujisawa, Takao
    Tanaka, Nobukazu
    Takeshita, Naohiro
    Onaga, Ryutaro
    Hoshi, Yuta
    Wada, Akihisa
    Sato, Masanobu
    Ueda, Yuri
    Tahara, Makoto
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [33] Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated with Immune Checkpoint Inhibitors
    Rodriguez, C. P.
    Fromm, J.
    Liao, J. J.
    Laramore, G. E.
    Lo, S. S.
    Goff, P. H.
    Santana-Davila, R.
    Martins, R. G.
    Futran, N.
    Houlton, J.
    Barber, B.
    Parvathaneni, U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E282 - E283
  • [34] Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials
    Dang, Shoutao
    Zhang, Shurong
    Zhao, Jingyang
    Li, Xinyu
    Li, Wei
    CANCER MEDICINE, 2023, 12 (20): : 20277 - 20286
  • [35] Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
    Lasniska, Izabela
    Kolenda, Tomasz
    Teresiak, Anna
    Lamperska, Katarzyna M.
    Galus, Lukasz
    Mackiewicz, Jacek
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (03) : 290 - 303
  • [36] Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy
    Airoldi, M
    De Stefani, A
    Marchionatti, S
    Pedani, F
    Gabriele, P
    Ragona, R
    Cortesina, G
    Bumma, C
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (04): : 298 - 304
  • [37] Pre-treatment characteristics and long-term outcomes of recurrent-metastatic head and neck cancer patients treated with immune checkpoint inhibitors
    Issa, M.
    Schultz, T.
    Xu, M.
    Bhateja, P.
    Karivedu, V.
    Dibs, K.
    Old, M.
    Kang, S.
    Gamez, M.
    Grecula, J.
    Jhawar, S.
    Mitchell, D.
    Seim, N.
    Agrawal, A.
    Ozer, E.
    Baliga, S. S. B. E.
    Carrau, R.
    Rocco, J.
    Blakaj, D.
    Bonomi, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S674 - S675
  • [38] Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
    Takuma Matoba
    Kiyoshi Minohara
    Daisuke Kawakita
    Gaku Takano
    Keisuke Oguri
    Akihiro Murashima
    Kazuyuki Nakai
    Sho Iwaki
    Hiroshi Tsuge
    Nobukazu Tanaka
    Sae Imaizumi
    Wataru Hojo
    Ayano Matsumura
    Koji Tsukamoto
    Shinichi Esaki
    Shinichi Iwasaki
    Scientific Reports, 12
  • [39] Impact of tumor burden on survival in patients with recurrent or metastatic head and neck cancer treated with immune checkpoint inhibitors
    Matoba, Takuma
    Minohara, Kiyoshi
    Kawakita, Daisuke
    Takano, Gaku
    Oguri, Keisuke
    Murashima, Akihiro
    Nakai, Kazuyuki
    Iwaki, Sho
    Tsuge, Hiroshi
    Tanaka, Nobukazu
    Imaizumi, Sae
    Hojo, Wataru
    Matsumura, Ayano
    Tsukamoto, Koji
    Esaki, Shinichi
    Iwasaki, Shinichi
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [40] Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
    Oliva, M.
    Spreafico, A.
    Taberna, M.
    Alemany, L.
    Coburn, B.
    Mesia, R.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2019, 30 (01) : 57 - 67
12345